RxDoctor Payments Data

Ariana Levin, MD

Glaucoma Specialist · Saint Louis, MONPI 1538666151

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,917 of the $25,245 with a category attached, or 74.9%. Alcon Research LLC accounts for 74.7% of it on its own, with 14 other manufacturers making up the rest.

$25,245in general payments, 2019–2025

Across 72 payments — averaging $350.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$19K
  • Alcon$4K
  • Sight Sciences, Inc.$681
  • AbbVie$595
  • Glaukos Corporation$470
  • Bausch & Lomb Americas Inc.$148
  • plus $572 from 9 others

What the payments were for

  • Consulting fees$18,91775%
  • Travel & lodging$1,6176%
  • Food & beverage$4,71119%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$224,632
Medicare patients
513
Services billed
1,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost109$47,901
RestasisCyclosporine49$42,413
CombiganBrimonidine Tartrate/Timolol96$39,249
RocklatanNetarsudil Mesylat/Latanoprost85$35,760
VyzultaLatanoprostene Bunod69$29,842
RhopressaNetarsudil Mesylate63$25,780
XiidraLifitegrast36$23,949
SimbrinzaBrinzolamide/Brimonidine Tart71$15,686
Brimonidine Tartrate278$12,638
Alphagan PBrimonidine Tartrate23$11,242
Travoprost33$9,462
Latanoprost819$7,502
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$7,008
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat426$6,015
Prednisolone Acetate168$5,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$595$140,806277 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$102$61,541148 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$148$53,791105 claims
AlconSimbrinza$3,916$15,68671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Missourion file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →